Cross-resistance to different aromatase inhibitors in breast cancer treatment

Endocrine-Related Cancer

Volumn 6, Issue 2, 1999, Pages 251-257

  Lonning P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; VOROZOLE;

AROMATIZATION; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; ENZYME BINDING; ESTROGEN BLOOD LEVEL; HUMAN; POSTMENOPAUSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTROGENS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 0033013878     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060251     Document Type: Article

References (48)

1. Brodie AMH, Schwarzel WC, Shaikh AA & Brodie HJ 1977 The effect of an aromatase inhibitor, 4-hydroxy-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100 1684-1695.
2. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter M, Azab M, Webster A & Plourde PV 1996 Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Journal of Clinical Oncology 14 2000-2011.
3. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A & Lee D 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83 1142-1152.
4. Clavel M & Catimel G 1993 Breast cancer: chemotherapy in the treatment of advanced disease. European Journal of Cancer 29A 598-604.
5. Coombes RC, Goss P, Dowsett M, Gazet J-C & Brodie A 1984 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet ii 1237-1239.
6. Coombes RC, Harper-Wynne C & Dowsett M 1999 Aromatase inhibitors and their use in the sequential setting. Endocrine-Related Cancer 6 259-263.
7. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U & Trunet PF 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
8. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P & Smith IE 1995 In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clinical Cancer Research 1 1511-1515.
9. Garcia-Giralt E, Ayme Y, Carton M, Daban A, Delozier T, Fargeot P, Fumoleau P, Gorins A, Guerin D, Guerin R, Maillart P, Mauriac L, May-Levin F, Metz R, Namer M, Olivier JP, Pommatau E, Pouillart P, Pujade-Lauraine E, Rouesse J, Serrou B, Vitse M & Zylberait D 1992 Second and third line hormone therapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Research and Treatment 24 139-145.
10. Geisler J, Johannessen DC, Anker G & Lønning PE 1996a Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. European Journal of Cancer 32A 789-792.
11. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO & Lønning PE 1996b Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer 74 1286-1291.
12. Geisler J, Lien EA, Ekse D & Lønning PE 1997 Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 63 53-58.
13. Geisler J, King N, Anker G, Ornati G, DiSalle E, Lønning PE & Dowsett M 1998a In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clinical Cancer Research 4 2089-2093.
14. Geisler J, Lundgren S, Berntsen H, Greaves JL & Lønning PE 1998b Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. Journal of Clinical Endocrinology and Metabolism 83 2687-2693.
15. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P & Lassus M 1998 Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology 9 639-645.
16. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P & Salle ED 1988 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. Journal of Steroid Biochemistry 30 391-394.
17. Horton R & Tait JF 1966 Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. Journal of Clinical Investigation 45 301-313.
18. Iveson TJ, Ahearn J & Smith IE 1993a Response to third-line endocrine treatment for advanced breast cancer. European Journal of Cancer 29A 572-574.
19. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF & Dowsett M 1993b Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Research 53 266-270.
20. Johannessen DC, Engan T, Salle ED, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S & Lønning PE 1997 Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clinical Cancer Research 3 1101-1108.
21. Jones AL, MacNeill F, Jacobs S, Lønning PE, Dowsett M & Powles TJ 1992 The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. European Journal of Cancer 28A 1712-1716.
22. de Jong PC, van de Yen J, Nortier HWR, Maitimu-Smeele I, Donker TH, Thijssen JHH, Slee PHTJ & Blankenstein RA 1997 Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Research 57 2109-2111.
23. Lønning PE & Ekse D 1995 A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 55 409-412.
24. Lønning PE & Kvinnsland S 1988 Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35 685-710.
25. Lønning PE, Kvinnsland S, Thorsen T & Ueland PM 1987 Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clinical Pharmacokinetics 13 393-406.
26. Lønning PE, Johannessen DC & Thorsen T 1989 Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. British Journal of Cancer 60 107-111.
27. Lønning PE, Dowsett M & Powles TJ 1990 Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. Journal of Steroid Biochemistry 35 355-366.
28. Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, McNeil F, Johannessen DC & Powles TJ 1992 Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment 23 57-62.
29. Lønning PE, Bajetta E, Murray R, Tubiana M, Eisenberg PD, Mickiewicz E, Fowst C, Arkhipov A, Polli A, diSalle E & Massimini GA 1998 Phase II study of exemestane (EXE) in metastatic breast cancer (MBC) patients failing non steroidal aromatase inhibitors (ns-AIs). Breast Cancer Research and Treatment 50 304 (Abstract).
30. Lundgren S 1992 Progestins in breast cancer treatment. Acta Oncologica 31 709-722.
31. Lundgren S, Helle SI & Lønning PE 1996 Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clinical Cancer Research 2 1515-1521.
32. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ & Dowsett M 1992 The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer 66 692-697.
33. MacNeill FA, Jacobs S, Lønning PE, Powles TJ & Dowsett M 1994 Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. British Journal of Cancer 69 1171-1175.
34. MacNeill FA, Jacobs S, Dowsett M, Lønning PE & Powles TJ 1995 The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemotherapy and Pharmacology 36 249-254.
35. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
36. Miller WR 1991 In vitro and in vivo effects of 4-hydroxyandrostenedione on steroid and tumour metabolism. In 4-hydroxyandrostenedione - a New Approach to Hormone-Dependent Cancer, pp 45-89. Eds RC Coombes & M Dowsett. London and New York: Royal Society.
37. Miller WR 1994 Importance of intratumour aromatase, and its susceptibility to inhibitors. In Aromatase Inhibition - Then, Now and Tomorrow, pp 43-53. Ed M Dowsett. London: Parthenon Publishing Group.
38. Miller WR, Telford J, Lowe C, Leonard RCF, Hillier S, Bischoff MA, Gundacker H & Dixon JMJ 1997 The effects of letrozole on in situ and in vitro oestrogen synthesis and endogenous oestrogen within the breast. Breast Cancer Research and Treatment 46 54.
39. Murray R & Pitt P 1985 Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. European Journal of Cancer and Clinical Oncology 21 19-22.
40. Murray R & Pitt P 1995 Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Research and Treatment 35 249-253.
41. Porkka K, Blomqvist C, Rissanen P, Elomaa I & Pyrhönen S 1994 Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. Journal of Clinical Oncology 12 1639-1647.
42. Reed MJ, Owen AM, Lai LC, Coldham NG, Ghilchik MW, Shaikh NA & James VHT 1989 In situ oestrone synthesis in normal breast and breast tumour tissue; effect of treatment with 4-hydroxyandrostenedione. International Journal of Cancer 44 233-237.
43. Reed MJ, Aherne GW, Ghilchik MW, Patel S & Chakraborty J 1991 Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. International Journal of Cancer 49 562-565.
44. Reed MJ, Topping L, Coldham NG, Purohit A, Ghilchik MW & James VHT 1993 Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. Journal of Steroid Biochemistry and Molecular Biology 44 589-596.
45. Samojlik E, Santen RJ & Wells SA 1977 Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. Journal of Clinical Endocrinology and Metabolism 45 480-487.
46. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978 Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 1257-1265.
47. Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roche H, Murray R, diSalle E, Lanzalone S, Zurlo MG & Piscitelli G 1997 Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. European Journal of Cancer 33 1767-1773.
48. Wall EVD, Donker TH, Frankrijker ED, Nortier HWR, Thijssen JHH & Blankenstein MA 1993 Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Research 53 4563-4566.